- Illumina announced updated EPS guidance and a cost reduction program for 2025.
- The company is addressing Chinese export restrictions and aims for revenue growth by 2027.
On March 10, 2025, Illumina announced an updated non-GAAP diluted EPS guidance for fiscal year 2025 and a cost reduction program. The company is addressing export restrictions imposed by China’s Ministry of Commerce, which could impact its revenue from the Greater China business. Despite these challenges, Illumina remains committed to expanding its multiomics portfolio and achieving high-single-digit revenue growth by 2027. The company expects a fiscal 2025 non-GAAP diluted EPS of approximately $4.50 and plans to implement a $100 million cost reduction program to mitigate potential revenue impacts from the Chinese market
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.